Attachment 1. Product Information for cobicistat
... patients receiving medications metabolized by CYP3A or initiating medications metabolized by CYP3A in patients already receiving TYBOST may result in increased plasma concentration of these concomitant medications. Higher plasma concentrations of concomitant medications can result in increased or pr ...
... patients receiving medications metabolized by CYP3A or initiating medications metabolized by CYP3A in patients already receiving TYBOST may result in increased plasma concentration of these concomitant medications. Higher plasma concentrations of concomitant medications can result in increased or pr ...
Oral anticoagulation in atrial fibrillation – Balancing the risk of stroke
... in severe residual deficit.3 Major bleeding is less often fatal and is less likely to cause serious residual effects.3 In patients with a CHADS2 score of 2 or more, the benefit of using an anticoagulant to prevent stroke often outweighs the risk of bleeding while taking therapy.3-5,8,9 The preferenc ...
... in severe residual deficit.3 Major bleeding is less often fatal and is less likely to cause serious residual effects.3 In patients with a CHADS2 score of 2 or more, the benefit of using an anticoagulant to prevent stroke often outweighs the risk of bleeding while taking therapy.3-5,8,9 The preferenc ...
Minocycline-induced pigmentation resolves after treatment with the Q-switched ruby laser Summary
... for 15 years for rosacea. He was not taking other medication. The temples, neck and scalp were treated with the Qswitched ruby laser at an energy fluence of 5 J/cm2 on four occasions at 3-month intervals without adverse effects. The grey–black pigmentation resolved without adverse effects revealing ...
... for 15 years for rosacea. He was not taking other medication. The temples, neck and scalp were treated with the Qswitched ruby laser at an energy fluence of 5 J/cm2 on four occasions at 3-month intervals without adverse effects. The grey–black pigmentation resolved without adverse effects revealing ...
Terlipressin - Therapeutic Goods Administration
... hyponatraemia and may be precipitated by infection, diuretics, nephrotoxic drugs, gastrointestinal bleeding or large volume paracentesis. It recommends that particular care should be taken to avoid renal impairment in patients at risk for HRS and that initial management involve correction of hypovol ...
... hyponatraemia and may be precipitated by infection, diuretics, nephrotoxic drugs, gastrointestinal bleeding or large volume paracentesis. It recommends that particular care should be taken to avoid renal impairment in patients at risk for HRS and that initial management involve correction of hypovol ...
Anticonvulsants - LSU School of Medicine
... • Epilepsy: Neurological disorder affecting the CNS. – Approximately 2.5 million people in the U.S. (~1% general pop) – Cost per patient ranges from $4,272 for persons with remission after initial diagnosis and treatment to $138,602 for persons with intractable and frequent seizures. ...
... • Epilepsy: Neurological disorder affecting the CNS. – Approximately 2.5 million people in the U.S. (~1% general pop) – Cost per patient ranges from $4,272 for persons with remission after initial diagnosis and treatment to $138,602 for persons with intractable and frequent seizures. ...
Induced Nausea and Vomiting - Journal of the Advanced
... • FDA approval: In combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, HEC • The metabolic route is an important differentiating factor • Mode ...
... • FDA approval: In combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, HEC • The metabolic route is an important differentiating factor • Mode ...
ANTIVIRAL AGENTS pharm
... bioavailability, necessitating frequent dosing, and may not provide maximum therapeutic benefit especially in immunocompromised hosts requiring higher plasma drug levels. Unwantedeffects Acyclovir generally is well tolerated. Topical acyclovir in a polyethylene glycol may cause mucosal irritation an ...
... bioavailability, necessitating frequent dosing, and may not provide maximum therapeutic benefit especially in immunocompromised hosts requiring higher plasma drug levels. Unwantedeffects Acyclovir generally is well tolerated. Topical acyclovir in a polyethylene glycol may cause mucosal irritation an ...
Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE
... It has been suggested that inflammatory damage in APMPPE is mediated by a type IV hypersensitivity reaction, and many lines of evidence appear to support this notion. As mentioned previously, tuberculin skin tests are found to be positive on many patients with APMPPE. Granulomatous inflammation was ...
... It has been suggested that inflammatory damage in APMPPE is mediated by a type IV hypersensitivity reaction, and many lines of evidence appear to support this notion. As mentioned previously, tuberculin skin tests are found to be positive on many patients with APMPPE. Granulomatous inflammation was ...
Lotrel - Novartis
... The most common reasons for discontinuation of therapy with Lotrel in these studies were cough and edema (including angioedema). The peripheral edema associated with amlodipine use is dose-dependent. When benazepril is added to a regimen of amlodipine, the incidence of edema is substantially reduced ...
... The most common reasons for discontinuation of therapy with Lotrel in these studies were cough and edema (including angioedema). The peripheral edema associated with amlodipine use is dose-dependent. When benazepril is added to a regimen of amlodipine, the incidence of edema is substantially reduced ...
REMERON ® (mirtazapine) Tablets
... Mirtazapine is a moderate antagonist at muscarinic receptors, a property that may explain the relatively low incidence of anticholinergic side effects associated with its use. Pharmacokinetics REMERON® (mirtazapine) Tablets are rapidly and completely absorbed following oral administration and have ...
... Mirtazapine is a moderate antagonist at muscarinic receptors, a property that may explain the relatively low incidence of anticholinergic side effects associated with its use. Pharmacokinetics REMERON® (mirtazapine) Tablets are rapidly and completely absorbed following oral administration and have ...
to see Full Prescribing Information for InnoPran XL
... 8.1 Pregnancy Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Intrauterine growth retardation, small placentas, and congenital anomalies have been reported for neonates whose mothers received propranolol HCl during pregnancy. ...
... 8.1 Pregnancy Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Intrauterine growth retardation, small placentas, and congenital anomalies have been reported for neonates whose mothers received propranolol HCl during pregnancy. ...
Transderm Sc¯op - Transderm Scop
... Skin burns have been reported at the patch site in several patients wearing an aluminized transdermal systems during a Magnetic Resonance Imaging scan (MRI). Because Transderm Scop® contains aluminum, it is recommended to remove the system before undergoing an MRI. Information for Patients Since sco ...
... Skin burns have been reported at the patch site in several patients wearing an aluminized transdermal systems during a Magnetic Resonance Imaging scan (MRI). Because Transderm Scop® contains aluminum, it is recommended to remove the system before undergoing an MRI. Information for Patients Since sco ...
patient information p atient in fo rm atio nphys ic ia n info
... In a rat embryo/fetal developmental toxicity study, pregnant rats received up to 25 mg/kg subcutaneously of oxybutynin chloride. Maternal systemic exposure was estimated to be 50 times that of women treated at the maximum recommended human dose (MRHD) of 36 mg, based on body surface area. No embryo/ ...
... In a rat embryo/fetal developmental toxicity study, pregnant rats received up to 25 mg/kg subcutaneously of oxybutynin chloride. Maternal systemic exposure was estimated to be 50 times that of women treated at the maximum recommended human dose (MRHD) of 36 mg, based on body surface area. No embryo/ ...
Managing patients taking novel oral
... to the invasiveness and difficulty of the surgery. To assess the risk of bleeding, patient-dependent factors and surgery-dependent factors must be considered together. In this sense an accurate anamnesis and surgical planning are extremely important to intercept these highrisk categories. Actually, ...
... to the invasiveness and difficulty of the surgery. To assess the risk of bleeding, patient-dependent factors and surgery-dependent factors must be considered together. In this sense an accurate anamnesis and surgical planning are extremely important to intercept these highrisk categories. Actually, ...
2nd T. 4th L. Updated
... 1. It irritates the gastric mucosa (direct acid effect and inhibition of cytoprotective PG synthesis). This may cause gastric and duodenal ulcers 2. It can precipitate bronchoconstriction (“aspirin asthma,” pseudoallergy) due to inhibition of PGE2 synthesis and overproduction of leukotrienes 3. Hepa ...
... 1. It irritates the gastric mucosa (direct acid effect and inhibition of cytoprotective PG synthesis). This may cause gastric and duodenal ulcers 2. It can precipitate bronchoconstriction (“aspirin asthma,” pseudoallergy) due to inhibition of PGE2 synthesis and overproduction of leukotrienes 3. Hepa ...
requip xl extended-release tablets
... Among the 613 patients who received REQUIP XL in clinical trials, there were 5 cases of sudden onset of sleep and 2 cases of motor vehicle accident in which it is not known if falling asleep was a contributing factor. During the 6-month trial in advanced Parkinson’s disease, somnolence was reported ...
... Among the 613 patients who received REQUIP XL in clinical trials, there were 5 cases of sudden onset of sleep and 2 cases of motor vehicle accident in which it is not known if falling asleep was a contributing factor. During the 6-month trial in advanced Parkinson’s disease, somnolence was reported ...
Quinidine for Pharmacological Cardioversion of Long-lasting
... In the daily clinical practice, patients with longlasting (>48 hours) AF are not uncommon. In these cases, the fast activation of atrial miocardiocytes causes a complex pattern of electrophysiological alterations, called “electrical remodeling”,4 which is able to change the pharmacological sensibili ...
... In the daily clinical practice, patients with longlasting (>48 hours) AF are not uncommon. In these cases, the fast activation of atrial miocardiocytes causes a complex pattern of electrophysiological alterations, called “electrical remodeling”,4 which is able to change the pharmacological sensibili ...
Diabetic maculopathy - Parkside Primary First
... it was less responsive to treatment with Anti-VEGF agents and the visual outcomes were worse in these patients. It is hypothesized that microenvironmental changes occurring in chronic DMO may need a treatment strategy that targets multiple inflammatory mediators. This is possible with corticosteroid ...
... it was less responsive to treatment with Anti-VEGF agents and the visual outcomes were worse in these patients. It is hypothesized that microenvironmental changes occurring in chronic DMO may need a treatment strategy that targets multiple inflammatory mediators. This is possible with corticosteroid ...
infections in patients with cancer
... 44.1%. In the two studies that reported the highest incidence of gram-positive pathogens, the majority of patients were administered prophylactic antibiotic drugs with predominately gram-negative coverage (i.e., colistin and quinolones). In contrast to these data, in the two studies in which prophyl ...
... 44.1%. In the two studies that reported the highest incidence of gram-positive pathogens, the majority of patients were administered prophylactic antibiotic drugs with predominately gram-negative coverage (i.e., colistin and quinolones). In contrast to these data, in the two studies in which prophyl ...
Tafluprost/Timolol - Therapeutic Goods Administration
... during the day over the study visits). Another 6-month study (n=564) compared TAPTIQOM 15/5 with the respective monotherapies in patients with open-angle glaucoma or ocular hypertension and mean untreated IOPs between 26-27 mmHg. Patients insufficiently controlled either with 0.0015% tafluprost (IOP ...
... during the day over the study visits). Another 6-month study (n=564) compared TAPTIQOM 15/5 with the respective monotherapies in patients with open-angle glaucoma or ocular hypertension and mean untreated IOPs between 26-27 mmHg. Patients insufficiently controlled either with 0.0015% tafluprost (IOP ...
HCPs only: Click here for product support
... during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and y ...
... during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and y ...
EMS5121
... during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and y ...
... during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and y ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.